SHPG : Summary for Shire plc - Yahoo Finance

U.S. Markets open in 26 mins.

Shire plc (SHPG)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
178.19+0.79 (+0.45%)
At close: 4:00PM EDT

179.22 1.03 (0.58%)
Pre-Market: 8:57AM EDT

People also watch
JAZZALXNBMRNMNKREGN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close177.40
Open0.00
Bid178.25 x 200
Ask178.35 x 400
Day's Range176.17 - 178.47
52 Week Range161.09 - 209.22
Volume786,492
Avg. Volume1,038,247
Market Cap53.86B
Beta1.71
PE Ratio (TTM)143.47
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.91 (0.51%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire4 hours ago

    INTUNIV® (Guanfacine Hydrochloride Prolonged Release), a Non-stimulant for the Treatment of ADHD, Receives Approval in Japan

    Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that its partner in Japan, Shionogi & Co., Ltd, has received the approval of the Japanese Ministry of Health, Labor and Welfare to manufacture and market INTUNIV. INTUNIV is a selective alpha-2A adrenergic receptor agonist.[1] With a unique mechanism of action, INTUNIV represents an additional treatment option in the management of ADHD.

  • Barrons.com3 days ago

    Shire: Can It Pay Down Debt?

    Gimme Credit is taking drug maker Shire (SHPG) to task today, but not for the load of debt it piled onto its once pristine balance sheet when it acquired U.S. drug make Baxalta last year. Rather, analyst Carol Levenson complains that while company has made progress paying down its management still doesn’t know how to talk to bond investors. According to Levenson, Shire, which unveiled terms of its $32 billion purchase of the Baxter (BAX) spinoff in January 2016, has never released detailed plans for deleveraging its balance sheet.

  • Shire (SHPG) Rare Disease Drug Gets Fast Track Designation
    Zacks7 days ago

    Shire (SHPG) Rare Disease Drug Gets Fast Track Designation

    Shire plc (SHPG) announced that the FDA has granted Fast Track designation for recombinant ADAMTS13 (SHP655) for the treatment of acute episodes of hereditary thrombotic thrombocytopenic purpura (hTTP).